JMP Securities initiated coverage on Vigil Neuroscience with a new price target
$VIGL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JMP Securities initiated coverage of Vigil Neuroscience with a rating of Mkt Outperform and set a new price target of $23.00